| STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. | lymphoma, |
| Study reveals that miR-155 acts as an oncogene by targeting TP53INP1 in esophageal squamous cell carcinoma. | esophageal, |
| microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma. | esophageal, |
| A novel network has been described in acute myeloid leukemia in which FLT3-ITD signaling induces oncogenic miR-155 by p65 and STAT5 thereby targeting transcription factor PU.1. | leukemia, |
| Data indicate a role of miR-155 in thiamine homeostasis and suggests a function of this oncogenic miRNA on breast cancer metabolism. | breast, |
| Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. | lymphoma, |
| The data indicate an oncogenic role for miR-155 in B-cell lymphoma which involves targeting the tumor suppressor NIAM. | lymphoma, |
| we defined a molecular mechanism by which EBV activates miR-155 expression in B-cell lymphoma cells (Fig. 6). Activation of miR-155 by EBV is one factor contributing to lymphocyte oncogenesis. AP1 proteins and DNA hypomethylation are essential elements for EBV-mediated miR-155 activation. | lymphoma, |
| miR-155 was overexpressed in the cervical cancer tissues as compared with normal tissues, suggesting an oncogenic role in cervical cancer. | cervical, |
| together with the increasingly apparent role for miR-155 in oncogenesis, and the upregulation of the IL-3 receptor alpha subunit in Acute Myeloid Leukemia | leukemia, |
| Our results show that two known oncogenic miRs, miR-155 and -92a were upregulated and the tumour suppressor miR-150 was downregulated in the lymph node proliferation centres in chronic lymphocytic leukaemia/small lymphocytic lymphoma | lymphoma, |
| Study reports disease stage-associated decrease of SATB1 expression in mycosis fungoides and an inverse expression of STAT5 and SATB1 in tumor cell lines. STAT5 inhibited SATB1 expression through induction of MIR155 providing mechanistic link between the proto-oncogenic JAK3/STAT5/MIR155 pathway, SATB1, and cytokines linked to cutaneous T-cell lymphoma severity and progression. | lymphoma, |
| Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. | None |
| miR-155 may function as an oncogene by targeting BACH1 | None |
| Study provide the first evidence that STAT5 drives expression of oncogenic BIC/miR-155 in cancer. | None |
| The oncogenic MicroRNA Hsa-miR-155-5p targets the transcription factor ELK3 and links it to the hypoxia response. | None |
| Loss of STAT4 expression and associated switch to Th2 phenotype during Mycosis Fungoides progression may be driven via aberrant histone acetylation and/or upregulation of oncogenic miR-155 microRNA. | None |
| miR-155 and miR-484 are potentially connected with sunitinib resistance and failure of the therapy. miR-155 is a known oncogene with direct influence on neovascularization. Biological role of miR-484 has to be clarified. | None |
| Additionally, in vitro and in vivo studies suggest miR-155 as an efficient therapeutic target, supporting its oncogenic function. The use of inhibiting anti-miR structures indicates promising potential as novel anticancer therapeutics. Reports from 53 studies prove that miR-155 has the potential to be a molecular tool in personalized medicine. [review] | None |
| Variant studies demonstrated that miRNA-155 has an oncogenic role in Waldenstrom_s Macroglobulinemia. [review] | None |